863031-21-4 | Azilsartan medoxomil

Availability
Typically In Stock

Description

• Catalog Number: AH81603
• Chemical Name: Azilsartan medoxomil
• CAS Number: 863031-21-4
• Molecular Formula: C30H24N4O8
• Molecular Weight: 568.5336
• MDL Number: MFCD19443688
• SMILES: CCOc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1noc(=O)[nH]1)c(ccc2)C(=O)OCc1oc(=O)oc1C

Computed Properties

• Complexity: 1100
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 42
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 10
• XLogP3: 4.9

Literature

• Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists.

  American journal of therapeutics 20140101

• Azilsartan medoxomil: a review of its use in hypertension.

  Clinical drug investigation 20120901

• [Azilsartan: a new angiotensin receptor blocker].

  Nihon rinsho. Japanese journal of clinical medicine 20120901

• Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.

  Hypertension (Dallas, Tex. : 1979) 20120801

• Assessment of the environmental fate and effects of azilsartan, a selective antagonist of angiotensin II type 1.

  Chemosphere 20120601

• [In vitro and in vivo pharmacological profiles of a novel angiotensin type 1-receptor blocker, azilsartan].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20120601

• Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120501

• Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.

  Journal of clinical hypertension (Greenwich, Conn.) 20120501

• Edarbyclor: an ARB/chlorthalidone combination for hypertension.

  The Medical letter on drugs and therapeutics 20120305

• New drugs 2012 part I.

  Nursing 20120301

• How full is our antihypertensives pipeline?

  Journal of pharmacology & pharmacotherapeutics 20120101

• Differential pharmacology and benefit/risk of azilsartan compared to other sartans.

  Vascular health and risk management 20120101

• New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil.

  Integrated blood pressure control 20120101

• What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?

  Cardiovascular diabetology 20120101

• Out-of-office blood pressure: from measurement to control.

  Integrated blood pressure control 20120101

• Critical evaluation of the efficacy and tolerability of azilsartan.

  Vascular health and risk management 20120101

• Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.

  Vascular health and risk management 20120101

• Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats.

  Diabetes, obesity & metabolism 20111201

• Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker.

  Journal of hypertension 20111201

• Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.

  The Annals of pharmacotherapy 20111201

• Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.

  European journal of pharmacology 20111101

• Azilsartan medoxomil: a new Angiotensin receptor blocker.

  Clinical therapeutics 20111101

• Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker.

  P & T : a peer-reviewed journal for formulary management 20111001

• Azilsartan medoxomil for the treatment of hypertension.

  Drugs of today (Barcelona, Spain : 1998) 20110901

• The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques.

  Journal of cardiovascular pharmacology 20110801

• Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.

  Journal of clinical hypertension (Greenwich, Conn.) 20110701

• Azilsartan medoxomil (Edarbi) the eighth ARB.

  The Medical letter on drugs and therapeutics 20110516

• New angiotensin-receptor blocker approved by FDA.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110401

• In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies.

  The Journal of pharmacology and experimental therapeutics 20110301

• Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.

  Hypertension (Dallas, Tex. : 1979) 20110301

• The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.

  Journal of clinical hypertension (Greenwich, Conn.) 20110201

• New drugs. Azilsartan medoxomil, belimumab, and lurasidone hydrochloride.

  Journal of the American Pharmacists Association : JAPhA 20110101

• Azilsartan: a newly approved angiotensin II receptor blocker.

  Cardiology in review 20110101

• Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk.

  Vascular health and risk management 20110101

• Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination.

  Integrated blood pressure control 20110101